DNA Nanobots, a Columbus, OH-based company which specializes in the design and delivery of DNA nanoparticles engineered for targeted therapeutics, raised an undisclosed amount in Pre-Seed funding.
The backers were not disclosed.
The company intends to use the funds to launch its BioPharma Partner Program to streamline its end-to-end custom biopharma solutions from design to development for preclinical and animal studies for improved delivery of a wide range of therapeutics.
Led by Jeff Spitzner, Ph.D., CEO, and Christopher Lucas, Ph.D., CSO, DNA Nanobots is a platform biotechnology company pioneering the use of functionalized DNA nanoparticles to address challenges associated with targeted delivery of therapeutic payloads. The company specializes in engineering custom cell-targeted solutions for partners to deliver drugs, nucleic acids, antibodies, and immunotherapies. To facilitate these partnerships, DNA Nanobots licensed a portfolio of DNA nanostructure (DNA origami) technologies from The Ohio State University and maintains an active collaboration with OSU Professor and company co-founder, Carlos Castro, Ph.D.
DNA is also developing its own pipeline of therapeutics for cancer and rare diseases.
